Blackstone Inc’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-340,793
Closed -$34.7M 174
2023
Q2
$34.7M Hold
340,793
0.15% 52
2023
Q1
$31M Hold
340,793
0.13% 49
2022
Q4
$12.9M Hold
340,793
0.05% 60
2022
Q3
$8.56M Hold
340,793
0.03% 72
2022
Q2
$10.4M Hold
340,793
0.03% 83
2022
Q1
$11.2M Hold
340,793
0.03% 102
2021
Q4
$8.99M Hold
340,793
0.02% 141
2021
Q3
$34.3M Hold
340,793
0.08% 85
2021
Q2
$48.2M Hold
340,793
0.11% 70
2021
Q1
$34M Hold
340,793
0.07% 69
2020
Q4
$42.1M Buy
340,793
+102,238
+43% +$13.4M 0.15% 52
2020
Q3
$23.2M Sell
238,555
-40,530
-15% -$5.06M 0.09% 62
2020
Q2
$43.5M Buy
+279,085
New +$42.4M 0.18% 40

Other funds holding RETA

Blackstone Inc's RETA Position: Q3 2023 in Review

Blackstone Inc sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 340,793 shares — an estimated $34.7M sold.

Blackstone Inc first reported a position in RETA in Q2 2020 and held it in 13 quarters. The position peaked at $48.2M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Blackstone Inc reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Blackstone Inc sold 340,793 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $34.7M.
  • Blackstone Inc first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 13 quarters.
  • Blackstone Inc's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $48.2M in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Blackstone Inc's 13F filing for Q3 2023, filed 14 Nov 2023.